Floatz logo

OFRANERGENE OBADENOVEC

Advanced and/or Metastatic Solid Organ Cancer

Vascular Biogenics Ltd. operating as VBL Therapeuticsgene_therapyPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

276 Active assets in the Advanced and/or Metastatic Solid Organ Cancer cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
I-Mab Biopharma US Limited
Phase 3BB
Irinotecan
Incyte Corporation
Phase 3BB
FILGRASTIM
Mayo Clinic
Phase 3BB
Pembrolizumab
InSilico Medicine Hong Kong Limited
Phase 2/3BB
Cyclophosphamide
InSilico Medicine Hong Kong Limited
Phase 2/3BB

View all 50 →

Same molecule, other indications

OFRANERGENE OBADENOVEC is also rated in:

ovarian cancerDormant
B
Indicative ·
61 / 100
View asset →
glioblastomaDormant
B
Indicative ·
56 / 100
View asset →
Colorectal Cancer With Hepatic MetastasesDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →